Population-level toxicity Coyne Scientific specializes in in vitro toxicity assays using large donor cohorts to predict drug safety across human genetic diversity, presenting a compelling value proposition for pharma companies seeking early, population-wide risk insights to de-risk candidates before late-stage trials.

Early-stage de-risking The company emphasizes helping sponsors curtail development on risky compounds early, while avoiding premature shelving of safe candidates, aligning with cost containment and faster decision cycles for pharmaceutical R&D.

Automated lab capacity Operating from a newly opened, highly automated 6,500 sq ft facility in Atlanta, CoyneSci can offer scalable, fast-turnaround testing services to accommodate drug pipelines with increasing throughput requirements.

Industry credibility Active involvement in Safety Pharmacology Society, Society of Toxicology, and other key groups enhances credibility with potential clients and provides networking channels for partnerships, referrals, and joint studies.

Tech-enabled marketing Current tech stack (WordPress, Google Cloud, analytics) supports efficient online presence and lead capture; opportunities exist to optimize digital campaigns targeting biotech and pharma decision-makers seeking advanced toxicity assays.